EUVIMEDEUVIMED entdecken
Multizentrische Studie

Effects of Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers on Prognosis in Acute Coronary Syndrome Patients with Preserved Ejection Fraction Undergoing Regular Dialysis

Yike Li, Enmin Xie, Qiang Chen, Yanxiang Gao, Zhen Meng, Changan Yu, Yaliu Yang, Zhaoxue Sheng, Conghan Fu, Limei Du, Wenyue Pang, Mulei Chen und 1 weitere

Cardiovascular Drugs and Therapy · 2025

DOI: 10.1007/s10557-025-07720-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Yike Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences, Peking Union…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Acute Coronary Syndrome, Stroke Volume, Angiotensin Receptor Antagonists. Die Arbeit nennt 28 Literaturangaben. Gefördert von: National High Level Hospital Clinical Research Funding, Capital's Founds for Health Improvement and Research, Beijing Research Ward Construction Clinical Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The utilization of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) following myocardial infarction (MI) is substantiated by evidence derived from trials conducted during the thrombolysis era. However, limited evidence suggests that ACEI/ARB confer benefits to patients with preserved left ventricular ejection fraction (LVEF). Notably, these studies typically exclude patients undergoing regular dialysis. In this study, we examined the association between the use of ACEI/ARB and the 5-year outcomes in patients with acute coronary syndrome (ACS) who are on regular dialysis and possess preserved left ventricular function. METHODS: This multicenter retrospective study enrolled a total of 1249 dialysis patients diagnosed with coronary heart disease (CAD). A total of 603 patients meeting the inclusion and exclusion criteria were analyzed. RESULTS: The mean age of the cohort was 61.7 years, with 70.6% being male; 313 (51.9%) patients were treated with ACEI/ARB. Over a 5-year follow-up period, the use of ACEI/ARB had no benefit on the composite outcome of major adverse cardiovascular events (MACE) (31.3% vs. 29.0%, p = 0.988). However, ACEI/ARBs reduced mortality across all causes (24.9% vs. 33.1%, p = 0.012) and cardiovascular deaths (14.7% vs. 21.4%, p = 0.015). Furthermore, ACEI/ARB demonstrated a more pronounced cardiovascular mortality benefit in patients with poorer left ventricular function (LVEF 50-60%). CONCLUSION: In dialysis patients with ACS and preserved left ventricular function, ACEI/ARB reduces all-cause and cardiovascular mortality. Additionally, a more pronounced survival benefit is observed in patients with impaired LVEF (50-60%). However, no benefit was found regarding MACE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin-Converting Enzyme InhibitorsAcute Coronary SyndromeStroke VolumeAngiotensin Receptor AntagonistsRenal DialysisVentricular Function, LeftHumansMaleFemaleMiddle AgedRetrospective StudiesAgedTreatment OutcomePrognosisRisk FactorsTime Factors

Stichwörter der Autor:innen

Acute coronary syndromeAngiotensin converting enzyme inhibitorsAngiotensin receptor blockersDialysis

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Cardiology, China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100029, China.
  • Department of Cardiology, Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.
  • Department of Cardiology, China-Japan Friendship Hospital, 2 Yinghua Dongjie, Beijing, 100029, China.
  • Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang, 110000, China. pwy1969@hotmail.com.
  • Department of Cardiology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China. chen_1758@126.com.
  • Department of Cardiology, China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100029, China. mdjingangzheng@yeah.net.

ORCID-Profile: Jingang Zheng

Förderung

  • National High Level Hospital Clinical Research Funding
  • Capital's Founds for Health Improvement and Research
  • Beijing Research Ward Construction Clinical Research Project
  • Capital’s Founds for Health Improvement and Research

Zitieren

APA

Li, Y., Xie, E., Chen, Q., Gao, Y., Meng, Z., Yu, C., Yang, Y., Sheng, Z., Fu, C., Du, L., Pang, W., Chen, M., & Zheng, J. (2025). Effects of Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers on Prognosis in Acute Coronary Syndrome Patients with Preserved Ejection Fraction Undergoing Regular Dialysis. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-025-07720-2

Vancouver

Li Y, Xie E, Chen Q, Gao Y, Meng Z, Yu C, et al. Effects of Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers on Prognosis in Acute Coronary Syndrome Patients with Preserved Ejection Fraction Undergoing Regular Dialysis. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-025-07720-2

BibTeX
@article{Li2025,
  author = {Li, Yike and Xie, Enmin and Chen, Qiang and Gao, Yanxiang and Meng, Zhen and Yu, Changan and Yang, Yaliu and Sheng, Zhaoxue and Fu, Conghan and Du, Limei and Pang, Wenyue and Chen, Mulei and Zheng, Jingang},
  title = {Effects of Angiotensin-Converting Enzyme Inhibitors/Angiotensin II Receptor Blockers on Prognosis in Acute Coronary Syndrome Patients with Preserved Ejection Fraction Undergoing Regular Dialysis},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2025},
  doi = {10.1007/s10557-025-07720-2}
}
Kostenlos starten →